ANI Pharma (ANIP) Misses Q4 EPS by 10c, Revenues Beat; Offers FY20 EPS/Revenue Guidance Below Consensus
ANI Pharma (NASDAQ: ANIP) reported Q4 EPS of $1.08, $0.10 worse than the analyst estimate of $1.18. Revenue for the quarter came in at $57.1 million versus the consensus estimate of $51.63 million.
For the fourth quarter 2019:
- Net revenues of $48.0 million versus $57.1 million in 2018
- GAAP net loss of $4.8 million and diluted GAAP loss per share of $0.41
- Adjusted non-GAAP EBITDA of $17.4 million
- Adjusted non-GAAP diluted earnings per share of $1.08
Arthur S. Przybyl, President and CEO, stated,
"ANI generated record net revenues and non-GAAP gross profit in 2019 while continuing to diversify its commercial product offering and pipeline opportunities. While revenues and non-GAAP gross profit for three of our important generic products were negatively impacted in recent periods, overall our business remains resilient, and we look forward to leveraging important recent launches such as Vancomycin Oral Solution and Bretylium Tosylate Injection as well as the recently acquired Amerigen portfolio in 2020. During 2019, we launched several new products, entered into collaborative arrangements with strategic partners and acquired both previously approved and development stage products we plan to launch in the future. We have utilized strong operating cash flows for asset acquisitions and investment into our portfolio of pipeline products and expect to continue to do so in the future.
During the fourth quarter, we successfully completed our fourth commercial scale batch of both Corticotropin API and the Cortrophin® Gel drug product, and importantly, remain on track to submit our supplemental NDA filing in March 2020."
GUIDANCE:
ANI Pharma sees FY2020 EPS of $4.46-$4.86, versus the consensus of $5.47. ANI Pharma sees FY2020 revenue of $213-223 million, versus the consensus of $229.15 million.
- Net revenues of $213 million to $223 million
- Adjusted non-GAAP EBITDA of $80 million to $86 million
- Adjusted non-GAAP diluted earnings per share of $4.46 to $4.86
For earnings history and earnings-related data on ANI Pharma (ANIP) click here.